Clinical factors predictive of long-term survival in advanced non-small cell lung cancer

Damme, Van; Govaerts, Elke; Nackaerts, Kristiaan; Dooms, Christophe; Wauters, Isabelle; Vansteenkiste, Johan

doi:10.1016/j.lungcan.2012.09.015

Cited by 22 publications

(22 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The previous studies of Van Damme et al (9) and Giroux Leprieur et al (8), as well as the present study, indicated that the response to first-line chemotherapy was a significantly important variable for long-term survival of >2 years.…”

Section: Discussionsupporting

confidence: 76%

“…In a study by Van Damme et al (9), long-term survivors were defined as patients who survived >2 years, and it was concluded that there are extremely few clinical factors at the time of diagnosis that can distinguish survivors of >2 years from survivors of ≤2 years. Compared with these results, the present study showed PS, relapse following thoracic surgery and metastatic sites as significant prognostic factors, which distinguished the ≥2–5 years group from the <2 years group.…”

Section: Discussionmentioning

confidence: 99%

“…While several studies (5–9) retrospectively defined a ≥2-year survival time in patients with advanced NSCLC as long-term survival, however, recently, other patients with advanced NSCLC have been encountered who have survived ≥5 years (10). Kaira et al (11) also reported the survival of patients with advanced NSCLC for ≥5 years.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis

et al. 2014

View full text Add to dashboard Cite

In order to examine which factors were important for achieving a ≥5 year survival time in non-small cell lung cancer (NSCLC) patients with distant metastasis, 268 NSCLC patients who received first-line chemotherapy between January 2004 and December 2007 were retrospectively examined. The median survival time of the patients was 14 months, with 22 surviving for ≥5 years, 48 for ≥2 years, but <5 years, and 198 surviving <2 years. Multivariate analysis determined that never having smoked, a good performance status, relapse following thoracic surgery and intra-thoracic metastasis were significantly favorable prognostic factors, while abdominal metastasis was a significantly poor prognostic factor. The ≥5 years and ≥2–5 years groups had significantly more favorable prognostic factors than the <2 years group. The never-smoked status was a particularly important factor for ≥5 years of survival. The ≥5 years and ≥2–5 years groups achieved a significantly more favorable response to first-line chemotherapy, and a greater number of regimens, total months of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment and cytotoxic agent treatment cycles compared with the <2 years group. In total, ~50% of the patients received palliative radiotherapy. In the ≥5 years group, patients with EGFR drug-sensitive mutations achieved ≥5 years of survival mainly by EGFR-TKI therapy, while those without EGFR mutations achieved ≥5 years of survival by continuing effective cytotoxic agents. Achievement of >5 years of survival was found to correlate with the presence of favorable prognostic factors, response to first-line chemotherapy, provision of appropriate EGFR-TKI therapy according to genetic testing results, continuing effective cytotoxic regimens and the use of radiotherapy as local therapy.

show abstract

Section: Discussionsupporting

confidence: 76%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…9 A few prior studies in the literature also examined long-term survival in advanced NSCLC patients, 11-12,32-38 yet these patients were predominantly treated with chemotherapy and not exposed to an EGFR-TKI. Although Nishino et al analyzed 5-year survival among advanced NSCLC patients treated with gefitinib (reporting a rate of 8.4%), 33 they also did not restrict the analysis to patients with sensitizing EGFR mutations, such that the presence of an activating EGFR mutation alone (in 37.9% of all patients and 14.3% of the 5-year survivors) emerged as a variable affecting survival.…”

Section: Discussionmentioning

confidence: 99%

“…10 Prior lung cancer studies available for review have similarly suggested an estimate of <5%. 11,12 To the best of our knowledge, no study to date has defined the rate of 5-year survival among patients with metastatic lung adenocarcinoma harboring sensitizing EGFR mutations who are then treated with EGFR-TKIs as targeted therapy.…”

Section: Introductionmentioning

confidence: 99%

Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs

Lin

Cardarella

Lydon

et al. 2016

Journal of Thoracic Oncology

295

244

View full text Add to dashboard Cite

Introduction Activating mutations in the epidermal growth factor receptor (EGFR) predict for prolonged progression-free survival in patients with advanced non-small cell lung cancer (NSCLC) treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) versus chemotherapy. Long-term survival outcomes, however, remain undefined. The objective of this study was to determine the 5-year survival in these patients, and identify clinical factors associated with overall survival (OS). Methods Patients with EGFR-mutant metastatic lung adenocarcinoma treated with erlotinib or gefitinib at Dana-Farber Cancer Institute between 2002 and 2009 were included. OS was analyzed. Results Among 137 patients, median PFS and OS were 12.1 months (95% CI, 10.2-13.5 months) and 30.9 months (95% CI, 28.2-35.7 months), respectively. Twenty patients (14.6%) were 5-year survivors. In multivariate analysis, exon 19 deletions (hazard ratio [HR], 0.63; 95% CI, 0.44-0.91; P = 0.01), absence of extrathoracic (HR 0.62; 95% CI, 0.41-0.93; P = 0.02) or brain metastasis (HR 0.48; 95% CI, 0.30-0.77, P = 0.002), and not a current smoker (HR 0.23; 95% CI, 0.09-0.59; P = 0.002) were associated with prolonged OS. Age, gender, stage at diagnosis, liver or bone or adrenal metastasis, specific TKI, and line of TKI therapy were not associated with OS. Conclusions Our data suggest that the prevalence of 5-year survival among EGFR-mutant metastatic lung adenocarcinoma patients treated with erlotinib or gefitinib is 14.6%. Exon 19 deletions and absence of extrathoracic or brain metastasis are associated with prolonged survival. Based on our findings, clinicians can gain an enhanced estimation of long-term outcomes in this population.

show abstract

Partial least‐squares discriminant analysis optimized by particle swarm optimization: application to ¹H nuclear magnetic resonance analysis of lung cancer metabonomics

Liu

Gong

et al. 2015

Journal of Chemometrics

View full text Add to dashboard Cite

The complexity of metabolic profiles makes chemometric tools indispensable for extracting the most significant information. Partial least-squares discriminant analysis (PLS-DA) acts as one of the most effective strategies for data analysis in metabonomics. However, its actual efficacy in metabonomics is often weakened by the high similarity of metabolic profiles, which contain excessive variables. To rectify this situation, particle swarm optimization (PSO) was introduced to improve PLS-DA by simultaneously selecting the optimal sample and variable subsets, the appropriate variable weights, and the best number of latent variables (SVWL) in PLS-DA, forming a new algorithm named PSO-SVWL-PLSDA. Combined with 1 H nuclear magnetic resonance-based metabonomics, PSO-SVWL-PLSDA was applied to recognize the patients with lung cancer from the healthy controls. PLS-DA was also investigated as a comparison. Relatively to the recognition rates of 86% and 65%, which were yielded by PLS-DA, respectively, for the training and test sets, those of 98.3% and 90% were offered by PSO-SVWL-PLSDA. Moreover, several most discriminative metabolites were identified by PSO-SVWL-PLSDA to aid the diagnosis of lung cancer, including lactate, glucose (α-glucose and β-glucose), threonine, valine, taurine, trimethylamine, glutamine, glycoprotein, proline, and lipid.

show abstract

Clinical factors predictive of long-term survival in advanced non-small cell lung cancer

Cited by 22 publications

References 15 publications

Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis

Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis

Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs

Partial least‐squares discriminant analysis optimized by particle swarm optimization: application to ¹H nuclear magnetic resonance analysis of lung cancer metabonomics

Contact Info

Product

Resources

About

Clinical factors predictive of long-term survival in advanced non-small cell lung cancer

Cited by 22 publications

References 15 publications

Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis

Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis

Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs

Partial least‐squares discriminant analysis optimized by particle swarm optimization: application to 1H nuclear magnetic resonance analysis of lung cancer metabonomics

Contact Info

Product

Resources

About

Partial least‐squares discriminant analysis optimized by particle swarm optimization: application to ¹H nuclear magnetic resonance analysis of lung cancer metabonomics